Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Agency for Science, Technology and Research | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A clinical trial to study the effects of dosage, infusion methods and complications of unfractionated heparin (UFH) treating acute progressive cerebral infraction was conducted. In this study, we observed the effects of four UFH treatments on 480 acute progressive cerebral infraction patients during from the 6th and the 72nd hour after the attack. It was concluded that the ultra-slow continuous intravenous infusion of UFH can significantly reduce the neurological deficit score of patients with progressive cerebral infarction, increase the cure rate, decrease the recurrence rate, and improve long-term quality of daily life. It is more effective than the treatment of intravenous infusion of low- molecular- weight UFH at once a day, and the risk of bleeding may not necessarily be increased.
Treatment' effectiveness rates of the four groups were 95.80%, 85.22%, 85.47%, and 87.72% respectively. The result of Group A was significantly different from those of Group B, C, and D (p <0.05). The adverse complication occurrence rates of the four groups were 5.88%, 3.48%, 4.27% and 3.51%.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| UFH,once a day | |||
| heparin Calcium,every 12 hours | |||
| dextran,Salviae,once a day | |||
| UFH,continuous intravenous infusion, |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| change of NIHSS at 4 weeks | the ultra-slow continuous intravenous infusion of UFH can significantly reduce the neurological deficit score of patients with progressive cerebral infarction, | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| the recurrence rate at 6 months | the ultra-slow continuous intravenous infusion of UFH can significantly decrease the recurrence rate of patients with progressive cerebral infarction, | 6 months |
| changs of ADL after 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
From May 2003 to October 2009 480 patients of acute progressive cerebral infraction that matched the standards above were included in the research.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| wang zh yong, professor | cangzhou hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine | Cangzhou | Hebei | 061001 | China |
Not provided
| Label | URL |
|---|---|
| cangzhou hospital | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
serum
the ultra-slow continuous intravenous infusion of UFH can significantly improve ADL of patients with progressive cerebral infarction
| 6 months |
| Number of patients with Adverse Events | The adverse complication occurrence rates of the four groups have no significantly different | 4 weeks |